Boston Scientific Corporation (NYSE: BSX) today announced one-year data from the INTREPID study, the first and only prospective, double-blind, randomized ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE